KAIYUAN SECURITIES·2025-10-20 14:44Group 1: Macro Economic Overview - The Q3 economic slowdown aligns with expectations, with GDP growth at 4.8% year-on-year, matching consensus forecasts, and a quarter-on-quarter increase of 1.1% [3][4] - The second industry has weakened significantly, particularly in the construction sector, which is expected to show a notable decline in GDP [3][4] - Exports have rebounded, boosting industrial production, while the service sector remains resilient, with industrial added value increasing by 1.3% year-on-year in September [3][4] Group 2: Real Estate Market Analysis - New housing transactions have weakened, with a significant year-on-year decline in sales volume observed in major cities, indicating a challenging market environment [11][13] - The average transaction area of new homes in 30 major cities fell by 3% compared to the previous two weeks, with year-on-year declines of 32% and 28% compared to 2023 and 2024, respectively [13][34] - Second-hand housing prices have also shown a downward trend, with a year-on-year decline of 5.2%, although the rate of decline has narrowed compared to previous months [33][37] Group 3: Fixed Income and Fiscal Policy - National public budget revenue increased by 0.5% year-on-year in the first nine months of 2025, while expenditure grew by 3.1% [16][17] - The central government allocated 500 billion yuan to local governments from debt limits, indicating a proactive fiscal policy approach [16][18] - Tax revenue has shown steady growth, with a notable increase in securities transaction stamp duty revenue, which rose by 342.4% year-on-year [17][19] Group 4: Industry-Specific Insights - The electric vehicle and battery management sectors are experiencing growth, with companies like Huazhi Jie expanding into new application areas such as new energy vehicles and drones [22][24] - The coal industry is witnessing a price surge, with thermal coal prices nearing 750 yuan per ton, driven by seasonal demand and supply constraints [44][45] - The pharmaceutical sector, represented by Guobang Pharmaceutical, is showing steady growth in performance and profitability, indicating a robust market position [47]